N-(Substituted benzyl)-8-hydroxy-1,6-naphthyridine-7carboxamides useful as HIV integrase inhibitors

Details for Australian Patent Application No. 2003220170 (hide)

Owner Merck & Co., Inc.

Inventors Langford, H Marie; Wai, John S; Perlow, Debbie S; Embrey, Mark; Melamed, Jeffrey Y; Egbertson, Melissa; Han, Wei; Zhuang, Linghang

Agent Spruson & Ferguson

Pub. Number AU-B-2003220170

PCT Number PCT/US03/07448

PCT Pub. Number WO2003/077850

Priority 60/364,929 15.03.02 US

Filing date 12 March 2003

Wipo publication date 29 September 2003

Acceptance publication date 11 December 2008

International Classifications

A61K 31/4375 (2006.01)

A61K 31/541 (2006.01) - Non-condensed thiazines containing further heterocyclic rings

A61K 31/549 (2006.01) - having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 31/18 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

Event Publications

31 July 2003 Complete Application Filed

  Priority application(s): 60/364,929 15.03.02 US

6 November 2003 Application Open to Public Inspection

  Published as AU-B-2003220170

11 December 2008 Application Accepted

  Published as AU-B-2003220170

9 April 2009 Standard Patent Sealed

21 January 2010 Amendment Made

  The nature of the amendment is: Amend the patentee name from Merck & Co., Inc. to Merck Sharp & Dohme Corp.

6 October 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003220171-Continuous sulfatase inhibiting progestogen hormone replacement therapy

2003220169-Use of carbon2-modified-19-nor-vitamin D analogs to induce the formation of new bone